A case of primary lung squamous cell carcinoma mimicking malignant mesothelioma producing granulocyte colony stimulating factor with chemotherapy (cisplatin and gemcitabine)-associated thrombotic thrombocytopenic purpura (TTP); An autopsy case report

Suzuki, Yasuhito; Kanazawa, Kenya; Kanai, Risa; Tomita, Haruyoshi; Saito, Mikako; Watanabe, Nobuhisa; Morimoto, Julia; Umeda, Takashi; Kawamata, Takaya; Rikimaru, Mami; Koizumi, Tatsuhiko; Togawa, Ryuichi; Sato, Yuki; Hirai, Kenichiro; Uematsu, Manabu; Minemura, Hiroyuki; Nikaido, Takefumi; Fukuhara, Atsuro; Sato, Suguru; Saito, Junpei; Tanino, Yoshinori; Mori, Kiyoshi; Shibata, Yoko

doi:10.1016/j.lungcan.2019.08.018

Cited by 5 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Daviet et al [ 11 ] reported that 119 cases of gemcitabine-associated TMA occurred mainly in the treatment of pancreatic cancer (52.9%) and lung cancer (12.6%). There are only a few published reports in which TMA was proven pathologically by renal biopsy or autopsy in lung cancer [ 12 ]. In our case, the patient was diagnosed with TMA 8.5 months after the initiation of gemcitabine treatment with a cumulative dose of 12.75 g/m 2 .…”

Section: Discussionmentioning

confidence: 99%

Thrombotic Microangiopathy Associated with Gemcitabine in Non-Small Cell Lung Cancer: A Case Report

et al. 2021

View full text Add to dashboard Cite

A 69-year-old man with refractory lung adenocarcinoma was treated with gemcitabine and vinorelbine. Dyspnea and hypertension developed after the 17th cycle of chemotherapy. Laboratory findings revealed intravascular hemolysis and renal dysfunction. Thrombotic microangiopathy (TMA) was confirmed by renal biopsy. Antihypertensive and steroid therapies were ineffective. After plasmapheresis, intravascular hemolysis and renal dysfunction gradually improved. However, the disease progressed, and he died 6 months after TMA diagnosis. Autopsy revealed similar pathological findings to those of the renal biopsy. It is important to discontinue gemcitabine at the onset of TMA and consider TMA when using gemcitabine for long periods.

show abstract

Section: Discussionmentioning

confidence: 99%